Capricor Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Capricor Therapeutics, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for June 4, 2026, detailing proposals for director elections, auditor ratification, executive compensation, and corporate governance amendments.
NASDAQ
Capricor Therapeutics is soliciting proxies for its 2025 Annual Meeting of Stockholders, including proposals for director elections, ratification of the accounting firm, approval of the 2025 Equity Incentive Plan, and an advisory vote on executive compensation.
NASDAQ
Capricor Therapeutics is holding its annual meeting on May 14, 2024, to vote on director elections, auditor ratification, executive compensation, and an increase in authorized common stock.